According to Vision Research Reports, the global chronic obstructive pulmonary disease treatment market size is expected to hit around US$ 26.31 billion by 2027 and projected to expand at a CAGR of 5.1% over the forecast period of 2020 to 2027.
Chronic obstructive pulmonary disease is a group of conditions affecting the lungs, which leads to difficulty in breathing. Chronic bronchitis and emphysema are two major indications included under chronic obstructive pulmonary disease (COPD). Breathlessness is a major characteristic of COPD. In case of emphysema, the alveoli (tiny air sacs) in the lungs are damaged. The walls of the alveoli are stretched, making the lungs bigger, resulting in difficulty in the movement of air. In chronic bronchitis, the bronchial airways (breathing tubes) inside the lungs are inflamed.
In terms of drug class, the combination therapy segment of the chronic obstructive pulmonary disease treatment market held a major share of the global COPD treatment market in 2019. It is likely to maintain its dominance in the chronic obstructive pulmonary disease treatment market during the forecast period, owing to its increased efficacy for COPD treatment. Based on distribution channel, the retail pharmacies segment of the COPD treatment market is estimated to account for a major share of the market. This segment of the chronic obstructive pulmonary disease treatment market is anticipated to expand at a rapid pace during the forecast period, owing to an increase in the number of COPD therapeutics being dispensed through retail pharmacies, and rise in the number of retail pharmacies in developing countries. Chronic obstructive pulmonary disease is characterized by progressive airflow limitation not fully reversible, and is a major cause of morbidity and mortality, worldwide. However, patent expiry of branded products and availability of generic equivalents and alternative treatment options are factors that are expected to hamper the growth of the global COPD treatment market during the forecast period.
Prominent Regions
North America held a major share of the global chronic obstructive pulmonary disease treatment market. The COPD treatment market in the region is primarily driven by factors such as highly structured healthcare industry and availability of well-defined reimbursement policies from private and public health insurance firms. In addition, extensive research and development to provide advanced and efficient products, and a large number of players in the region, are factors driving the chronic obstructive pulmonary disease treatment market in North America. The chronic obstructive pulmonary disease market in Asia Pacific is estimated to witness significant growth. Asia Pacific is a relatively untapped COPD treatment market as compared to developed regions. Hence, the region offers immense growth opportunities to market players. Factors such as high prevalence of chronic obstructive pulmonary disease, rise in geriatric population, surge in patient population, and growth of the healthcare industry are fueling the expansion of the COPD treatment market in the region.
Europe held the second-largest share of the global chronic obstructive pulmonary disease treatment market in 2018. Well-developed healthcare infrastructure and increase in the number of incidences of chronic obstructive pulmonary disease are driving the COPD treatment market in the region. The chronic obstructive pulmonary disease treatment markets in the Middle East & Africa and Latin America are projected to witness moderate growth in the near future.
Key Players
Key players are expanding their footprint to strengthen their position in the global chronic obstructive pulmonary disease treatment market. Emerging economies, due to increase in the number of patient population, and rise in tobacco smoking and air population, offer lucrative opportunities to key players to increase their market share. Manufacturers are engaging in new product development, collaborations, acquisitions, and distribution agreements. For instance, in July 2018, Orion Corporation signed a multi-year licensing agreement with Menarini to distribute and commercialize the former’s Easyhaler products. According to the agreement, Menarini would be supplying Orion’s products in Asia Pacific countries such as China, the Philippines, Malaysia, Hong Kong, Indonesia, Vietnam, Thailand, Singapore, South Korea, and Taiwan.
Prominent players operating in the global chronic obstructive pulmonary disease treatment market are AstraZeneca, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.), CHIESI Farmaceutici S.p.A., Orion Corporation, and Mylan N.V.
Increase in Prevalence of Chronic Obstructive Pulmonary Disease: A Key Driver of COPD Treatment Market
Increase in Adoption of Combination Therapy: A Key Driver of COPD Treatment Market
Patent Expiry of Branded Products and Availability of Generic Equivalents Hamper Market
Market Segmentation
COPD Treatment Market by Drug Class
COPD Treatment Market by Distribution Channel
COPD Treatment Market by Region
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017–2027
4.4.1. Market Revenue (US$ Mn) Projection
5. Market Outlook
5.1. Innovative Solutions for COPD Treatment
5.2. Pipeline Analysis
6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.3.1. Combination Therapy
6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
6.3.1.3. Triple Therapy
6.3.1.4. Others
6.3.2. Corticosteroids
6.3.3. Bronchodilators
6.3.3.1. Long Acting Beta Agonist (LABA)
6.3.3.2. Short Acting Beta Agonist (SABA)
6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
6.3.4. Phosphodiesterase Type 4 Inhibitors
6.3.5. Mucokinetics
6.3.6. Others
6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class
7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel
8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region
9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. Combination Therapy
9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
9.2.1.3. Triple Therapy
9.2.1.4. Others
9.2.2. Corticosteroids
9.2.3. Bronchodilators
9.2.3.1. Long Acting Beta Agonist (LABA)
9.2.3.2. Short Acting Beta Agonist (SABA)
9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
9.2.4. Phosphodiesterase Type 4 Inhibitors
9.2.5. Mucokinetics
9.2.6. Others
9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country/Sub-region
10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. Combination Therapy
10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
10.2.1.3. Triple Therapy
10.2.1.4. Others
10.2.2. Corticosteroids
10.2.3. Bronchodilators
10.2.3.1. Long Acting Beta Agonist (LABA)
10.2.3.2. Short Acting Beta Agonist (SABA)
10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
10.2.4. Phosphodiesterase Type 4 Inhibitors
10.2.5. Mucokinetics
10.2.6. Others
10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. Combination Therapy
11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
11.2.1.3. Triple Therapy
11.2.1.4. Others
11.2.2. Corticosteroids
11.2.3. Bronchodilators
11.2.3.1. Long Acting Beta Agonist (LABA)
11.2.3.2. Short Acting Beta Agonist (SABA)
11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
11.2.4. Phosphodiesterase Type 4 Inhibitors
11.2.5. Mucokinetics
11.2.6. Others
11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. Combination Therapy
12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
12.2.1.3. Triple Therapy
12.2.1.4. Others
12.2.2. Corticosteroids
12.2.3. Bronchodilators
12.2.3.1. Long Acting Beta Agonist (LABA)
12.2.3.2. Short Acting Beta Agonist (SABA)
12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
12.2.4. Phosphodiesterase Type 4 Inhibitors
12.2.5. Mucokinetics
12.2.6. Others
12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. Combination Therapy
13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
13.2.1.3. Triple Therapy
13.2.1.4. Others
13.2.2. Corticosteroids
13.2.3. Bronchodilators
13.2.3.1. Long Acting Beta Agonist (LABA)
13.2.3.2. Short Acting Beta Agonist (SABA)
13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
13.2.4. Phosphodiesterase Type 4 Inhibitors
13.2.5. Mucokinetics
13.2.6. Others
13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)
14.3. Company Profiles
14.3.1. AstraZeneca
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Boehringer Ingelheim International GmbH
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Novartis AG
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. CHIESI Farmaceutici S.p.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Orion Corporation
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Mylan N.V.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis